Back to results
US 2013/0296302 A1Published application
1h-pyrazolo[3,4-b]pyridines and therapeutic uses thereof
AssigneeSamumed, LLC
InventorsJohn Hood, Sunil Kumar KC, David Mark Wallace
Life of this patent
Estimating the term…
Abstract
Provided herein are compounds according to Formulas (I) or (II) and pharmaceutically acceptable salts thereof, and compositions comprising the same, for use in various methods, including treating cancer, abnormal cellular proliferation, angiogenesis, Alzheimer's disease, lung disease, osteoarthritis, idiopathic pulmonary fibrosis and neurological conditions/disorders/diseases.
Claims65
A compound or pharmaceutically acceptable salt or prodrug thereof having the structure of Formula I:
- wherein:
- R1 and R2 are independently selected from the group consisting of H, lower alkyl, halide, —(C1-9 alkyl)naryl(R6)q, —(C1-9 alkyl)nheteroaryl(R7)q, —(C1-9 alkyl)nheterocyclyl(R8)q, —(C1-9 alkyl)nN(R9)2, —OR10 and —NHC(═O)R11;
- R3 is selected from the group consisting of H, halide and lower alkyl;
- with the proviso that at least two of R1, R2 and R3 are H;
- R4 and R5 are independently selected from the group consisting of H, —C(═O)N(R12)2, -aryl(R13)q, -heterocyclyl(R14)q, and -heteroaryl(R15)q;
- with the proviso that at least one of R4 and R5 is H;
- each R6 is a substituent attached to the aryl ring and independently selected from the group consisting of H, —C1-9 alkyl, halide, CF3 and CN;
- each R7 is a substituent attached to the heteroaryl ring and independently selected from the group consisting of H, —C1-9 alkyl, halide, CF3 and CN;
- each R8 is a substituent attached to the heterocyclyl ring and independently selected from the group consisting of H, halide, —(C1-3 alkyl)naryl(R6)q, and —C1-4 alkyl;
- each R9 is independently selected from the group consisting of H, —C1-9 alkyl, —(C1-3 alkyl)naryl(R6)q, —(C1-3 alkyl)ncarbocyclyl and —(C1-9 alkyl)N(R16)2;
- alternatively, two adjacent R9 or two adjacent R12, may be taken together with the atoms to which they are attached to form a heterocyclyl(R17)q;
- R10 is selected from the group consisting of H, —CF3, —(C1-3 alkyl)naryl(R6)q, and —C1-9 alkyl;
- R11 is selected from the group consisting of —(C1-3 alkyl)naryl(R6)q, —(C1-3 alkyl)ncarbocyclyl, —C1-9 alkyl and —CF3;
- each R12 is independently selected from the group consisting of H, —(C1-9 alkyl)naryl(R6)q and —C1-9 alkyl;
- each R13 is a substituent attached to the aryl ring and independently selected from the group consisting of H, halide, —CF3, CN, —(C1-3 alkyl)nheterocyclyl(R8)q, —(C1-9 alkyl)nN(R9)2 and —(C1-9 alkyl)nNHSO2R18;
- each R14 is a substituent attached to the heterocyclyl ring and independently selected from the group consisting of H, lower alkyl, halide, —CF3 and CN;
- each R15 is a substituent attached to the heteroaryl ring and independently selected from the group consisting of H, lower alkyl, halide, —CF3, CN, —C(═O)(C1-3 alkyl), —(C1-9 alkyl)nN(R9)2 and —(C1-9 alkyl)nNHSO2R18;
- each R16 is independently selected from the group consisting of H and lower alkyl;
- each R17 is a substituent attached to the heterocyclyl ring and independently selected from the group consisting of H, —(C1-9 alkyl)naryl(R6)q, and —C1-9 alkyl;
- each R18 is a lower alkyl;
- A is N or C;
- with the proviso that if A is N then R2 is nil;
- each q is an integer of 1 to 5;
- each n is an integer of 0 or 1;
- and
- with the proviso that Formula I is not a structure selected from the group consisting of:
23 more elements
A compound or pharmaceutically acceptable salt or prodrug thereof having the structure of Formula II:
- wherein:
- R1 and R2 are independently selected from the group consisting of H, lower alkyl, halide, —(C1-9 alkyl)naryl(R6)q, —(C1-9 alkyl)nheteroaryl(R7)q, —(C1-9 alkyl)nheterocyclyl(R8)q, —(C1-9 alkyl)nN(R9)2, —OR10 and —NHC(═O)R11;
- R3 is selected from the group consisting of H, halide and lower alkyl;
- with the proviso that at least two of R1, R2 and R3 are H;
- R4 and R5 are independently selected from the group consisting of H, —C(═O)N(R12)2, -aryl(R13)q, -heterocyclyl(R14)q, and -heteroaryl(R15)q;
- with the proviso that at least one of R4 and R5 is H;
- each R6 is a substituent attached to the aryl ring and independently selected from the group consisting of H, —C1-9 alkyl, halide, CF3 and CN;
- each R7 is a substituent attached to the heteroaryl ring and independently selected from the group consisting of H, —C1-9 alkyl, halide, CF3 and CN;
- each R8 is a substituent attached to the heterocyclyl ring and independently selected from the group consisting of H, halide, —(C1-3 alkyl)naryl(R6)q, and —C1-4 alkyl;
- each R9 is independently selected from the group consisting of H, —C1-9 alkyl, —(C1-3 alkyl)naryl(R6)q, —(C1-3 alkyl)ncarbocyclyl and —(C1-9 alkyl)N(R16)2;
- alternatively, two adjacent R9 or two adjacent R12, may be taken together with the atoms to which they are attached to form a heterocyclyl(R17)q;
- R10 is selected from the group consisting of H, —CF3, —(C1-3 alkyl)naryl(R6)q, and —C1-9 alkyl;
- R11 is selected from the group consisting of —(C1-3 alkyl)naryl(R6)q, —(C1-3 alkyl)ncarbocyclyl, —C1-9 alkyl and —CF3;
- each R12 is independently selected from the group consisting of H, —(C1-9 alkyl)naryl(R6)q and —C1-9 alkyl;
- each R13 is a substituent attached to the aryl ring and independently selected from the group consisting of H, halide, —CF3, CN, —(C1-3 alkyl)nheterocyclyl(R8)q, —(C1-9 alkyl)nN(R9)2 and —(C1-9 alkyl)nNHSO2R18;
- each R14 is a substituent attached to the heterocyclyl ring and independently selected from the group consisting of H, lower alkyl, halide, —CF3 and CN;
- each R15 is a substituent attached to the heteroaryl ring and independently selected from the group consisting of H, lower alkyl, halide, —CF3, CN, —C(═O)(C1-3 alkyl), —(C1-9 alkyl)nN(R9)2 and —(C1-9 alkyl)nNHSO2R18;
- each R16 is independently selected from the group consisting of H and lower alkyl;
- each R17 is a substituent attached to the heterocyclyl ring and independently selected from the group consisting of H, —(C1-9 alkyl)naryl(R6)q, and —C1-9 alkyl;
- each R18 is a lower alkyl;
- A is N or C;
- with the proviso that if A is N then R2 is nil;
- each q is an integer of 1 to 5;
- each n is an integer of 0 or 1;
- and
- with the proviso that Formula II is not a structure selected from the group consisting of:
23 more elements
Dependencies are inferred from the claim text.